A new report on the cost of dispensing prescription medications brings into sharp focus the difficult economic challenges faced by retail pharmacy operators. It should come as no surprise that the study — conducted by Abt Associates and the MPI Group for the National Association of Chain Drug Stores, the National Community Pharmacists Association and
ARLINGTON, Va. – On the day before National Prescription Drug Take Back Day, the National Association of Chain Drug Stores today thanked the lead U.S. House of Representatives sponsors of H.R. 5628, the Access to Increased Drug Disposal Act of 2018, for their introduction of bipartisan legislation that is consistent with the spirit of NACDS’
WASHINGTON — Former Eli Lilly and Co. executive Alex Azar has been confirmed by the Senate as the new secretary of the U.S. Department of Health & Human Services (HHS). Nominated for the HHS secretary post in November by President Donald Trump, Azar was approved by the Senate on Wednesday in a 55-43 vote, mainly
WASHINGTON — Sens. John McCain (R., Ariz.) and Tammy Baldwin (D., Wis.) and Rep. Jan Schakowsky (D., Ill.) this week reintroduced the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act, aimed at improving cost transparency for pharmaceutical price hikes. The FAIR Drug Pricing Act would require drug manufacturers to notify the Department of Health
WASHINGTON – Pharmacist provider status legislation is back before Congress, with the bipartisan co-sponsorship of more than a quarter of the Senate. Sens. Chuck Grassley (R., Iowa), Bob Casey (D., Penn.) and Sherrod Brown (D., Ohio) on Thursday reintroduced the Pharmacy and Medically Underserved Areas Enhancement Act (S. 109) with its 27 original co-sponsors. A
PITTSBURGH — In what chief executive officer Heather Bresch called “an extraordinary commercial response,” Mylan N.V. plans to release a generic version of its EpiPen epinephrine auto-injector for anaphylaxis, answering public demands to lower the cost of the potentially life-saving product. Mylan said Monday that its U.S. subsidiary expects to roll out the generic EpiPen
NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the
